Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status

Table 1 Basic characteristics

	Microsatellite instability-high, n = 2358		Microsatellite stable, n = 19593
	Immunotherapy, n = 142	Chemotherapy, n = 860	Immunotherapy, n = 88	Chemotherapy, n = 8085
Follow up duration (month)
mean ± SD	21.91 ± 12.23	19.83 ± 12.89	18.48 ± 11.37	20.61 ± 11.71
Median (Range)	22.46 (0.53-48.76)	18.58 (0.26-48.69)	18.88 (0.79-47.31)	30.52 (0-49.97)
Age (yr)
mean ± SD	72.32 ± 14.70	62.43 ± 14.42	66.10 ± 15.41	61.53 ± 13.38
Median (Range)	77 (27-90)	63 (21-90)	67.5 (27-90)	62 (19-90)
< 65, n (%)	34 (23.94)	465 (54.07)	39 (44.32)	4661 (57.65)
≥ 65, n (%)	108 (76.06)	395 (45.93)	49 (55.68)	3424 (42.35)
Sex, n (%)
Male	52 (36.62)	437 (50.81)	48 (54.55)	4466 (55.24)
Female	90 (63.38)	423 (49.19)	40 (45.45)	3619 (44.76)
Race, n (%)
White	9 (6.34)	47 (5.47)	76 (6.36)	6356 (78.61)
Black	123 (86.62)	679 (78.95)	8 (9.09)	1123 (13.89)
Other	9 (6.34)	125 (14.53)	0	8 (0.10)
Unknown	1 (0.70)	9 (1.05)	4 (4.41)	598 (7.4)
Charlson-Deyo Score, n (%)
0	9 (6.34)	644 (74.88)	65 (73.86)	6039 (74.69)
1	123 (86.62)	132 (15.35)	16 (18.18)	1260 (15.58)
2	9 (6.34)	43 (5.00)	6 (6.82)	400 (4.95)
≥ 3	1 (0.70)	41 (4.77)	1 (1.14)	386 (4.77)
Tumor size, n (%)
≤ 20 mm	107 (75.35)	623 (72.44)	61 (69.32)	5621 (69.52)
> 20 mm	35 (24.65)	237 (27.56)	27 (30.68)	2464 (30.48)
Tumor grade, n (%)
Well differentiated	0	0	0	0
Moderate differentiated	0	0	0	0
Poorly differentiated	0	0	0	0
Unknown	142 (100.00)	860 (100.00)	88 (100.00)	8085 (100.00)

SD: Standard deviation.